The phase III European Tarceva vs. Chemotherapy (EURTAC) trial also showed a significant benefit for erlotinib (9.7 months PFS) compared to chemotherapy (5.2 months PFS) in EGFR-mutant patients.Osimertinib is widely approved for the first-line treatment of patients with advanced NSCLC who have EGFR activating mutations.Cancer development relies heavily on aberrant activation of EGFR, which drives excessive cell proliferation and differentiation. Here, EGFR is linked to non-small cell lung carcinoma.